3.12 USD
↗ 0.32 (11.43%)AT CLOSE (11:59 AM EDT)
Galectin Therapeutics Inc.
GALTNASDAQ • USD
3.44
↗ 0.32 (10.19%)
POST MARKET (AS OF 07:59 PM EDT)
Post Market
AS OF 07:59 PM EDT
3.44
↗ 0.32 (10.19%)
Market: CLOSED
Galectin Therapeutics Inc. (GALT) trades at $3.13 per share. There is a divergence between signals — technical indicators rate "Buy" but underlying fundamentals lean "Sell". This is driven by a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, exceptional Return on Equity (20.0%) and a bearish Death Cross on the long-term moving averages.
Technical & fundamental data as of Jun 23, 2026.
Open?$2.71
High?$3.70
Low?$2.71
Prev. Close?$2.80
Volume?3.9M
Avg. Volume?323.7K
VWAP?$3.40
Rel. Volume?12.07x
Bid / Ask
Bid?$2.55 × 100
Ask?$3.74 × 100
Spread?$1.19
Midpoint?$3.15
Valuation & Ratios
Market Cap?184.4M
Shares Out?65.9M
Float?43.7M
Float %?66.3%
P/E Ratio?N/A
P/B Ratio?-1.40
EPS?-$0.40
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
Employees
9
Market Cap
186.0M
Industry
PHARMACEUTICAL PREPARATIONS
Website
Listed
2002-09-04
Address
4960 PEACHTREE INDUSTRIAL BOULEVARD
NORCROSS, GA 30071
Phone: 678-620-3186
NORCROSS, GA 30071
Phone: 678-620-3186
Technical OutlookBuy
Strong SellNeutralStrong Buy
Long-Term (Tide)?– Neutral(0/3)
Medium-Term (Wave)?▲ Bullish(+3/3)
Short-Term (Ripple)?▲ Bullish(+2/3)
MA Alignment?Mixed
Full Technical Analysis →Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?3
Z-Score?0
Momentum?50
Short Sent.?19
Piotroski F-Score?0/9Weak
Altman Z-Score?-40.89Distress
Confidence?51%Low
Short InterestVery High
Short % of Float?17.55%High
Short Interest?7.7M
Days to Cover?19.7
Free Float43.7M
Avg Daily Volume388.8K
Settlement Date2026-05-29
Financial Health
Current Ratio?2.15Strong
Quick Ratio?2.15Strong
Cash Ratio?1.93Strong
Debt/Equity?-0.25Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score100/100
P/E?N/A▾
P/B?-1.40CHEAP▾
S&P97
P/S?N/A▾
P/FCF?N/A▾
EV/EBITDA?-12.5CHEAP▾
S&P97
EV/Sales?N/A▾
Returns & Efficiency
ROE?20.0%STRONG▾
Peers50
S&P66
ROA?-167.8%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?N/A
Enterprise Value?$203.2M
Fundamentals ratios updated end of day